Filter posts

I-MAK’s Distorted View of the U.S. Patent System

In an opinion piece published at CNBC.com, Tahir Amin — co-founder of I-MAK — blames …

Insurers Shift Costs and Facts

As health insurance companies begin setting rates for 2019, many consumers are once again faced …

The Latest Good News on Prescription Drug Costs

Two-hundred biotech allies from more than 40 different states visited Washington D.C. this week. These …

President’s Cancer Panel Recommends Shift Towards Value

This week, the President’s Cancer Panel published a new report entitled “Promoting Value, Affordability, and …

ICER Comes Under Renewed Scrutiny

As we enter a new and exciting era of medicine, there is an important question …

#BIOCEO18: A Bright Future

“A transformative year in medicine.” That’s how BIO President and CEO Jim Greenwood recently described …

Here We Go Again (But In a Good Way)

“We achieved the lowest drug trend since we began measuring drug trend data in 1993.” …

Five Questions for the Senate Hearing on Prescription Drugs

On Tuesday, the Senate Committee on Health, Education, Labor, and Pensions will hold its third …

Insurers Distort the Facts on Drug Costs … Again

An effort by the Blue Cross Blue Shield Association (BCBSA) to spur a discussion on …

A Flawed Bill That Would Harm Seniors

The Medicare prescription drug program has been a remarkable success for both seniors and taxpayers, …